1. Home
  2. SILC vs CGEN Comparison

SILC vs CGEN Comparison

Compare SILC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silicom Ltd

SILC

Silicom Ltd

SELL

Current Price

$42.59

Market Cap

259.1M

Sector

Technology

ML Signal

SELL

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.28

Market Cap

191.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SILC
CGEN
Founded
1987
1993
Country
Israel
Israel
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.1M
191.1M
IPO Year
2002
2001

Fundamental Metrics

Financial Performance
Metric
SILC
CGEN
Price
$42.59
$2.28
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
158.9K
311.3K
Earning Date
04-30-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.17
N/A
Revenue Next Year
$12.28
$75.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.34
$1.30
52 Week High
$52.95
$3.24

Technical Indicators

Market Signals
Indicator
SILC
CGEN
Relative Strength Index (RSI) 49.39 54.27
Support Level $38.07 $1.48
Resistance Level $50.42 $2.35
Average True Range (ATR) 4.68 0.09
MACD -0.28 0.05
Stochastic Oscillator 34.64 95.52

Price Performance

Historical Comparison
SILC
CGEN

About SILC Silicom Ltd

Silicom Ltd is engaged in designing, manufacturing, marketing, and supporting high-performance networking and data infrastructure solutions for a broad range of servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, Switches, Edge AI Solutions, Edge Networking Accessories, 4G 5G Products, FPGA-Based Cards, and Others. Its geographic areas are the USA, North America - other, Israel, Europe, and Asia-Pacific. It derives a majority of its revenue from the USA.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: